March 2, 2016
Initiation of Operations for Drug Product Manufacturing Facility in China
Tokyo, Japan, March 2, 2016---Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") announced, Kyowa Hakko Kirin China Pharmaceutical Co., Ltd. (Shanghai, China, President & General Manager: Hidetoshi Hirooka, "Kyowa Hakko Kirin China"), a subsidiary of Kyowa Hakko Kirin, will start the operations of drug product manufacturing facility from March 2016 in China.
Construction of new facility is a part of restructuring our business operations for sustainable growth in China. The facility will start packaging of the imported tablets for Chinese market, and Kyowa Hakko Kirin China plans to manufacture of REGPARA® tablets in the future.
The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
<External Appearance of New Facility>
<New facility overview>
|Facility name:||Drug Product Manufacturing Facility|
|Scale:||Reinforced-Concrete construction, one story, total floor area of approx. 1,392.5 m2|
|Investment:||Approx. 1 billion yen|
|Purpose:||Manufacture of oral preparations|
|Schedule:||Start of operations: March 2016|